



Brief Report

COVID-19 CROUP IS OBSERVED IN OLDER CHILDREN DURING THE OMICRON WAVE IN NEW YORK CITY

Nisha Narayanan, MD,^{*,†} Samantha Langer, MD,[†] Karen P. Acker, MD,[†] Steven D. Rosenblatt, MD,[‡]
 Will Simmons, MPH,[§] Alan Wu, MS,[§] Jin-Young Han, MD, PHD,[†] Erika L. Abramson, MD, MSC,^{†,§}
 Zachary M. Grinspan, MD, MS,^{†,§} and Deborah A. Levine, MD^{*,†}

^{*}Department of Emergency Medicine, [†]Department of Pediatrics, [‡]Department of Otolaryngology, NewYork-Presbyterian/Weill Cornell Medicine, New York, and [§]Department of Population Health Sciences, Weill Cornell Medicine, New York, New York
 Corresponding Address: Nisha Narayanan, Department of Emergency Medicine, Weill Cornell Medicine, 525 E 68th St, M130, New York, NY, 10021.

Abstract—Background: The Omicron variant of SARS-CoV-2 has a predilection for the upper airways, causing symptoms such as sore throat, hoarse voice, and stridor. **Objective:** We describe a series of children with COVID-19-associated croup in an urban multicenter hospital system. **Methods:** We conducted a cross-sectional study of children ≤ 18 years of age presenting to the emergency department during the COVID-19 pandemic. Data were extracted from an institutional data repository comprised of all patients who were tested for SARS-CoV-2. We included patients with a croup diagnosis by *International Classification of Diseases, 10th revision* code and a positive SARS-CoV-2 test within 3 days of presentation. We compared demographics, clinical characteristics, and outcomes for patients presenting during a pre-Omicron period (March 1, 2020–December 1, 2021) to the Omicron wave (December 2, 2021–February 15, 2022). **Results:** We identified 67 children with croup, 10 (15%) pre-Omicron and 57 (85%) during the Omicron wave. The prevalence of croup among SARS-CoV-2-positive children increased by a factor of 5.8 (95% confidence interval 3.0–11.4) during the Omicron wave compared to prior. More patients were ≥ 6 years of age in the Omicron wave than prior (19% vs. 0%). The majority were not hospitalized (77%). More patients ≥ 6 years of age received epinephrine therapy for croup during the Omicron wave (73% vs. 35%).

Most patients ≥ 6 years of age had no croup history (64%) and only 45% were vaccinated against SARS-CoV-2. **Conclusion:** Croup was prevalent during the Omicron wave, atypically affecting patients ≥ 6 years of age. COVID-19-associated croup should be added to the differential diagnosis of children with stridor, regardless of age. © 2022 Elsevier Inc. © 2022 Elsevier Inc. All rights reserved.

Keywords—COVID-19; croup; laryngotracheitis; SARS-CoV-2

INTRODUCTION

Understanding how COVID-19 affects children is important, as is understanding the changing clinical landscape as new variants of the virus emerge. Compared with previous variants of SARS-CoV-2, the Omicron variant has shown a predilection for the upper airways, manifesting as sore throat and hoarse voice in adults and croup in children (1,2). Croup is a clinical syndrome characterized by inspiratory stridor, barking cough, and hoarseness due to the added narrowing of small subglottic airways by viral-induced inflammation. It typically occurs in children between 6 months and 3 years of age, and is rare in children ≥ 6 years of age old because of the larger diameter of their airways (3,4). Here, we describe the

Reprints are not available from the authors.

RECEIVED: 7 July 2022; FINAL SUBMISSION RECEIVED: 16 August 2022;
 ACCEPTED: 4 September 2022

Table 1. Demographic Characteristics of Patients With SARS-CoV-2 Croup^a

Characteristic	Pre-Omicron, n = 10	Omicron, n = 57	p Value
Median age, years (IQR)	2.00 (1.00–3.00)	2.00 (1.00–5.00)	0.7
Age, years, n (%)			
<3	5 (50)	36 (63)	
3 to <6	5 (50)	10 (18)	
6 to <12	0 (0)	11 (19)	
Sex, n (%)			>0.9
Female	3 (30)	20 (35)	
Male	7 (70)	37 (65)	
Race/ethnicity, n (%)			0.5
White	2 (20)	21 (37)	
Hispanic or Latino or Spanish origin	3 (30)	20 (35)	
American Indian or Alaska Native	0 (0)	1 (1.8)	
Asian	2 (20)	4 (7.0)	
Black or African American	0 (0)	2 (3.5)	
Other combinations not described	1 (10)	3 (5.3)	
Unknown	2 (20)	6 (11)	
Admission status, n (%)			0.5
Not admitted	8 (80)	44 (77)	
Admission to floor	1 (10)	11 (19)	
Admission to PICU	1 (10)	2 (3.5)	
Medical complexity, ^b n (%)			0.4
No chronic disease	9 (90)	39 (68)	
Noncomplex chronic disease	0 (0)	10 (18)	
Complex chronic disease	1 (10)	8 (14)	

IQR = interquartile ratio; PICU = pediatric intensive care unit.

^a Patients ≤ 18 years of age with 1+ emergency department visit with 1) 1+ croup diagnosis within 24 h after presentation and 2) 1+ positive SARS-CoV-2 polymerase chain reaction laboratory assessment ± 3 days from presentation.

^b Defined using the Pediatric Medical Complexity Algorithm (8).

17 clinical characteristics and disease course of a pediatric
18 case series of COVID-19–associated croup from a multi-
19 center hospital system in a large urban center during the
20 COVID-19 pandemic in New York City.

21 METHODS

22 We conducted a cross-sectional study of patients ≤ 18
23 years old who presented to 3 affiliated urban pediatric
24 emergency departments (EDs) during the COVID-19 pan-
25 demic. This study was approved by the Weill Cornell
26 Medicine Institutional Review Board. Data were extracted
27 from the Weill Cornell Medicine COVID-19 Institu-
28 tional Data Repository, which aggregates data on patients
29 tested for SARS-CoV-2 from electronic health records
30 of NewYork-Presbyterian/Weill Cornell Medical Center
31 (5). Patients were divided into pre-Omicron (March 1,
32 2020–December 1, 2021) and Omicron waves (Decem-

ber 2, 2021–February 15, 2022). Cohort date ranges were
33 selected based on the prevalence of SARS-CoV-2 vari-
34 ants as reported by the New York City Department of
35 Health and Mental Hygiene data (6). We included ED pa-
36 tients with a croup diagnosis within 24 h of presentation
37 (*International Classification of Diseases, 10th revision*
38 codes J05.0, R06.1, 464.2, and J04.2), and a positive
39 nasopharyngeal reverse transcription polymerase chain
40 reaction SARS-CoV-2 test within 3 days of presentation
41 (7). Repeat visits within 3 days of a previous visit were
42 considered a single clinical course. Abstracted data were
43 corroborated with manual chart review. We reported pa-
44 tient demographic and clinical characteristics, including
45 age, sex, race, ethnicity, vaccination status, and medical
46 complexity as defined using the Pediatric Medical Com-
47 plexity Algorithm (8). We also reported clinical outcomes
48 such as disposition, medication administration, and need
49 for respiratory support.
50

Table 2. Clinical Characteristics of Patients With Croup^a During the Omicron Wave

Characteristic	<6 mo, n = 2	3 y to <6 y, n = 10	6 mo to <3 y, n = 34	6 y to <12 y, n = 11
Median age, years (IQR)	0.00 (0.00–0.00)	4.00 (4.00–5.00)	1.00 (1.00–2.00)	8.00 (6.50–9.00)
Vaccines, n (%)				
0	2 (100)	7 (70)	34 (100)	5 (45)
1	0 (0)	2 (20)	0 (0)	1 (9.1)
2	0 (0)	1 (10)	0 (0)	5 (45)
History of croup, n (%)	0 (0)	4 (40)	3 (8.8)	4 (36)
Steroid, n (%)	2 (100)	10 (100)	33 (97)	11 (100)
Racemic epinephrine, n (%)	1 (50)	2 (20)	13 (38)	8 (73)
Racemic epinephrine doses, n (%)				
1	0 (0)	2 (100)	6 (46)	7 (88)
2	0 (0)	0 (0)	5 (38)	0 (0)
3	1 (100)	0 (0)	1 (7.7)	0 (0)
4	0 (0)	0 (0)	0 (0)	1 (12)
5	0 (0)	0 (0)	1 (7.7)	0 (0)
Intramuscular epinephrine, n (%)	0 (0)	1 (10)	0 (0)	1 (9.1)
Respiratory support, n (%)	0 (0)	0 (0)	2 (5.9)	1 (9.1)
Admitted, n (%)	1 (50)	2 (20)	8 (24)	1 (9.1)
Admission location				
Floor	1 (100)	2 (100)	7 (88)	0 (0)
ICU	0 (0)	0 (0)	1 (12)	1 (100)
Median inpatient LOS, days (IQR)	1.10 (1.10–1.10)	0.90 (0.50–2.15)	1.20 (1.10–2.60)	1.50 (1.50–1.50)
Median ICU LOS, days (IQR)	NA	NA	4.10 (4.10–4.10)	NA

ICU = intensive care unit; IQR = interquartile ratio; LOS = length of stay; NA = not available.

^a Patients ≤ 18 years of age with 1+ emergency department visit with (1) 1+ croup diagnosis within 24 h after presentation and (2) 1+ positive SARS-CoV-2 polymerase chain reaction laboratory assessment ± 3 days from presentation.

RESULTS

Our cohort included 1751 pediatric patients in the ED who tested positive for SARS-CoV-2, of which 865 (49%) were during the Omicron wave. We identified 67 of these children with croup; 10 (15%) in the pre-Omicron period and 57 (85%) during the Omicron wave. The prevalence of croup among COVID-19–positive children increased by a factor of 5.8 (prevalence ratio = 5.8, 95% confidence interval 3.0–11.4) during the Omicron wave compared with the pre-Omicron period. Table 1 describes patient demographics and disposition. The median age was similar for both groups, but more patients ≥ 6 years of age were in the Omicron group (0 vs. 19%). Most patients were not hospitalized (80% in pre-Omicron vs. 77% in Omicron wave). Comprehensive viral testing was performed in 34% of patients with croup, with only 4 coinfections noted.

Table 2 describes the clinical characteristics of the 57 patients with croup in the Omicron wave.

The majority affected were <3 years of age (61%), and 19% were ≥ 6 years of age. All patients ≥ 6 years of age presented during the Omicron period. Though most children received steroids, more patients ≥ 6 years of age received racemic epinephrine, suggesting a more severe initial presentation with stridor at rest than in younger children (73% vs. 35%). No patients were given remdesivir. The most severe case was a 10-year-old who required multiple doses of racemic and intramuscular epinephrine, oxygen, and admission to the intensive care unit. Most older patients (64%), including the aforementioned patient, had no history of croup. All of these patients demonstrated significant improvement in their stridor with ED intervention and no additional work-up, such as radiography, otolaryngology consult, or laryngoscopy was performed. In this ≥ 6 years of age group,

86 in which all patients were eligible for the COVID-19 vac-
87 cine, only 45% were fully vaccinated with 2 doses.

88 DISCUSSION

89 We found an increased prevalence of croup during the
90 COVID-19 Omicron wave, notably among an older cohort
91 of children than were affected in the pre-Omicron period.
92 Most older children had no history of croup and were
93 undervaccinated for COVID-19. Although few patients
94 were hospitalized, most required steroids and racemic
95 epinephrine, suggesting a more severe ED presentation
96 than in younger children.

97 The association of the Omicron variant and croup has
98 been previously described (2,9). We identified an older
99 subgroup of croup patients who, historically, have rarely
100 been affected (3). Animal models have demonstrated the
101 Omicron variant's predilection for the upper respiratory
102 tract compared with lung parenchyma (10). This vari-
103 ant has also been associated with acute odynophagia and
104 severe sore throat in adults (11). It is unclear whether
105 the variant's direct effects on the upper airways or a
106 host inflammatory response accounts for the clinical pre-
107 sentation of croup in this unusual age group. Further
108 investigations are needed to understand the mechanisms
109 driving this association.

110 Limitations

111 The study is limited by its small sample size and data
112 from a single urban health care system. Although we can-
113 not confirm the SARS-CoV-2 variant causing infection,
114 the time periods in this study were based on New York
115 City Omicron variant testing (6). The impact of viral coin-
116 fection is unclear because of a lack of comprehensive viral
117 testing. In addition, our database may not have captured
118 all vaccination data external to our hospital system.

119 CONCLUSIONS

120 In summary, we found an increased prevalence of
121 COVID-19-associated croup during the Omicron wave
122 atypically affecting older children. COVID-19-associated
123 croup should now be considered in the differential diag-
124 nosis of older children presenting with stridor. Further
125 investigation is needed to elucidate the pathophysiology
126 of COVID-19-associated croup to assist with diagnosis
127 and management of these children.

ACKNOWLEDGMENTS

128

This work was supported by the RTW Charitable Foun- 129
dation and by NewYork-Presbyterian Hospital and Weill 130
Cornell Medical College, including the Clinical and 131
Translational Science Center (UL1 TR000457) and Joint 132
Clinical Trials Office. The RTW Charitable Foundation, 133
NewYork-Presbyterian Hospital, and Weill Cornell Med- 134
ical College had no role in the design and conduct of the 135
study. N.N., K.A., and D.L. conceptualized and designed 136
the study, coordinated and supervised data collection, 137
drafted the initial manuscript, and reviewed and revised 138
the manuscript. S.L., W.S., and A.W. designed the data 139
collection instruments, collected data, carried out the ini- 140
tial analyses, and reviewed and revised the manuscript. 141
S.R., E.A., Z.G., and J-Y.H. conceptualized and designed 142
the study and critically reviewed the manuscript for im- 143
portant intellectual content. All authors approved the final 144
manuscript as submitted and agreed to be accountable for 145
all aspects of the work. 146

REFERENCES

147

1. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, du- 148
ration, and risk of hospital admission in individuals infected with 149
SARS-CoV-2 during periods of omicron and delta variant dom- 150
inance: a prospective observational study from the ZOE COVID 151
Study. *Lancet* 2022;399:1618–24. 152
2. Brewster RCL, Parsons C, Laird-Gion J, et al. Covid-19-associated 153
croup in children. *Pediatrics* 2022;149. 154
3. Johnson DW. Croup. *BMJ Clin Evid* 2014;2014:0321. 155
4. Smith DK, McDermott AJ, Sullivan JF. Croup: diagnosis and man- 156
agement. *Am Fam Physician* 2018;97:575–80. 157
5. Sholle ET, Kabariti J, Johnson SB, et al. Secondary Use of Patients' 158
Electronic Records (SUPER): an approach for meeting specific data 159
needs of clinical and translational researchers. *AMIA Annu Symp* 160
Proc 2018;2017:1581–8. 161
6. NYC.gov. COVID-19-data, variants. Available at: [https://www1. 162
nyc.gov/site/doh/covid/covid-19-data-variants.page](https://www1.nyc.gov/site/doh/covid/covid-19-data-variants.page). Accessed 163
April 22, 2022. 164
7. Hanna J, Brauer PR, Morse E, Berson E, Mehra S. Epidemiological 165
analysis of croup in the emergency department using two national 166
datasets. *Int J Pediatr Otorhinolaryngol* 2019;126. 167
8. Simon TD, Haaland W, Hawley K, Lambka K, Mangione-Smith R. 168
Development and validation of the Pediatric Medical Complexity 169
Algorithm (PMCA) version 3.0. *Acad Pediatr* 2018;18:577–80. 170
9. Tunç EM, Shin CKJ, Usoro E, et al. Croup during the coronavirus 171
disease 2019 Omicron variant surge. *J Pediatr* 2022;247:147–9. 172
10. Hui KP, Ho JC, Cheung M-chun, et al. SARS-COV-2 Omicron 173
variant replication in human bronchus and lung ex vivo. *Nature* 174
2022;603:715–20. 175
11. Piersiala K, Kakabas L, Bruckova A, Starkhammar M, Cardell LO. 176
Acute odynophagia: a new symptom of COVID-19 during the 177
SARS-CoV-2 Omicron variant wave in Sweden. *J Intern Med* 178
2022;292:154–61. 179

Q2

ARTICLE SUMMARY**1. Why is this topic important?**

Understanding how COVID-19 affects children is important, as is understanding the changing clinical landscape as new variants of the virus emerge. The Omicron variant of SARS-CoV-2 appears to cause croup in older children in which the disease rarely presents.

2. What does this study attempt to show?

This study describes the clinical characteristics and disease course of a pediatric case series of COVID-19 croup from a multicenter hospital system in a large urban center during the COVID-19 pandemic in New York City.

3. What are the key findings?

Children ≥ 6 years of age, in which croup is typically rare, presented with croup during the Omicron wave of SARS-CoV-2. Most of this older cohort required steroids and racemic epinephrine, suggesting a more severe ED presentation than in younger children.

4. How is patient care impacted?

COVID-19-associated croup should now be considered in the differential diagnosis of older children presenting with stridor and/or respiratory distress.